Nelson Dusetti: Guiding treatment decisions for operable and metastatic patients with PDAC

Nelson Dusetti posted on X:

“We discuss here the dual resistance to mFOLFIRINOX and gemcitabine, the role of transcriptomic signatures in reducing toxicity and guiding treatment decisions for operable and metastatic patients reinforcing their potential for personalized treatment.

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Nelson Dusetti, Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.